BioGend Therapeutics Co., Ltd. (6733.TWO) stock: key figures, P/E, revenue and dividend
Health Care · Taiwan
BioGend Therapeutics Co., Ltd. financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 167.65 m TWD | 222.34 m TWD |
| Gross profit | 130.51 m TWD | 160.16 m TWD |
| Operating income | -122.26 m TWD | -109.70 m TWD |
| EBIT | -128.03 m TWD | -103.46 m TWD |
| Net income | -116.47 m TWD | -84.61 m TWD |
| Diluted EPS – continuing operations | – | -0.68 TWD |
Full history since 2020, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About BioGend Therapeutics Co., Ltd.
BioGend Therapeutics Co., Ltd. engages in the research and development, and sale of orthopedic medical devices and related products. The company offers RevoCart, an autologous cartilage repair system; and SoufCut, an autologous adipose tissue collection system. It develops BiG-001, an osteoinductive bone graft substitute; BiG-006 for lumbar interbody fusion; and BiG-009, an autologous cartilage repair system for articaular cartilage. The company operates in Taiwan, Hongkong, Chinese Mainland, and Malaysia. BioGend Therapeutics Co., Ltd. was founded in 2016 and is based in Taipei, Taiwan.
More stocks
- TDM Berhad (2054.KL)
- Tainet Communication System (4905.TWO)
- HENNESSY ADVISORS INC (HNNA)
- Jushi Holdings Inc. (JUSH)
- Daejung Chemicals & Metals Co.Ltd (120240.KQ)
- CGRE AG (CGX.DE)
- Taiwan Line Tek Electronic Co Ltd (2462.TW)
- Afluente Transmissão de Energia Elétrica S.A (AFLT3.SA)
- VIB Vermoegen (VIH1.DE)
- Crimson Wine Group, Ltd (CWGL)
- DY Corporation (013570.KS)
- Y-Entec Co. Ltd (067900.KQ)
Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.